56 - Monitoring Safety and Efficacy in Phase 2 (S4E11)

All right, diving in today, getting into the
nitty gritty, the really crucial stage of bringing
new meds to folks. We're talking phase two clinical
trials. Yeah, you can picture it like think of
it like this super important fact finding mission,
right? OK, yeah. We've seen, you know, some promising
hints, some glimmers in the lab, some early data.
And now we're like, all right. Let's take the
show on the road. Let's see how this drug actually
works, how it behaves, but this time, it's in
actual people who are dealing with the condition
we're aiming at. It's like, are we on the right
path here? Does it have the potential to help?
But also, are there any surprises, any bumps
in the road we didn't see coming? Exactly. Got
to find those out early. Absolutely. Phase two
is where the rubber meets the road. It's that
make or break moment. It really is. We start
to see... Does this thing actually work like
we hoped it would in the people we want to help?
Yeah. But, equally important, we gotta be super
thorough checking for any short -term side effects.
any risks and figure out the right dose to use
if we're going to do bigger studies later. Right.
Got to get the dosage right. You got it. And
the information we get from phase two, that's
gold, seriously. It's like the foundation for
everything else. It basically decides if this
drug keeps going, if we keep developing it, or
if we have to head back to the drawing board.
High stakes. And for today's deep dive, you've
really gone all out on the research. Transcripts,
excerpts, books. We went deep. We got into the
science of how drugs actually interact with the
body. We're talking pharmacokinetics here, all
the way to the regulations, the rules set out
by the big dogs, the FDA and the ICH. The FDA,
right, and the ICH, the International Council
for Harmonization. That's the one. And we even
touched on how they design drugs at the molecular
level, medicinal chemistry, and how digital tools
are, you know, shaking things up in the process.
We've got the full picture. the whole enchilada,
and our goal today is to walk you through the
systems they use, how they keep tabs on everything
during these trials, how they capture all that
crucial data, and what they do when something
unexpected pops up, those rapid response strategies.
Okay, I like that, rapid response. You gotta
be ready, because in phase two, patient safety
is the absolute top priority, no question. But
at the same time, we're trying to find those
early signs that the drug is actually doing what
it's supposed to, that it's having a positive
effect. It's a balancing act for sure. It really
is, a delicate dance. All right, so let's rewind
for a sec. We've talked about preclinical testing
before, all the lab work, animal studies, that
sort of thing. But why is the monitoring in phase
two so... Intense like what actually changes
when we go from the lab to testing in real people
great question Because even though those preclinical
studies give us a ton of valuable info about
safety You know is this thing toxic phase two
is the first time we're putting this drug into
a much more complex system meaning The human
body. Bingo. And not just any human body, a human
body that's dealing with the specific disease
we're targeting. Right, which adds another layer
of complexity. Exactly. And there are all these
variations, these differences between people
that we just can't fully replicate in the lab
or in animals. Like, what, give me some examples.
Sure, think about genetics, right? Everyone's
got a unique genetic makeup. that can affect
how their body processes the drug. Makes sense.
Then there's just the overall way people's bodies
work, their physiology. Some people might absorb
the drug faster than others, some slower. And
people are taking other medications, have other
conditions too, right? Exactly. So all of that
can influence how a drug gets into the body,
how it spreads around, how it gets broken down,
how it gets eliminated. We call this whole process
pharmacokinetics. Pharmacokinetics. It's like
a whole journey the drug takes through the body.
It is a complex journey with many stops. Okay,
so each person's body is handling the drug a
little differently. What does that mean for safety?
Well, it means there's always a chance that something
unexpected could pop up. Something we didn't
see in the animals. Even if the drug seems safe
in the lab. Even then. Because sometimes there
are differences between species. What's safe
for a mouse might not be safe for a human or
a side effect might only show up in humans. That's
a bit unnerving. It can be, but that's why phase
two is so important. It's where we start to get
a real understanding of the drug's safety profile
in the actual people we want to treat. We're
building that safety net. Right. And you mentioned
the FDA and the ICH before. I'm guessing they
have something to say about all this. Oh, absolutely.
They've set up these really strict guidelines
for safety monitoring during phase two. It shows
how important it is to get this right, to balance
the need for data with the absolute priority
of patient safety. It's like a tightrope walk.
You got it. We're always on the lookout for those
early signs that the drug is actually helping,
that it's doing what it's designed to do, but
we can never, ever compromise on safety. Gotcha.
So... Let's get specific here. What are the researchers
actually looking at? What kind of data are they
gathering during phase two to make sure everything's
okay? Okay, so there are a few key areas. First
up, adverse events. We call them AOEs. AEs, all
right. Basically, anything that happens that's
unfavorable, unintended, like a bad sign, a new
symptom, a health condition, anything like that
that happens during the trial. So it doesn't
even matter if they think it's caused by the
drug. Doesn't matter. We write everything down.
It's like if you get a headache during the trial,
that goes in the report. Even if it's just a
normal headache, not because of the drug. Even
then. Might seem like overkill, but here's the
thing. OK. Later on, we do all these fancy statistical
analyses. And let's say, just for example, we
see that more people taking the drug get headaches
than people taking the placebo. OK, so a pattern
emerges. Right. It could be a total coincidence,
or it could be an early sign that the drug is
having some effect we didn't expect, maybe on
a different part of the body. Interesting. So
you catch it early before it becomes a bigger
problem. Exactly. That's why we got to be so
thorough. And then, of course, we're checking
those basic vital signs all the time. Real vital
signs, yeah. Heart rate, blood pressure, all
that good stuff. All of it. Temperature, respiratory
rate. We track it all at very specific times,
according to the study plan, and that lets us
see even small changes that might be linked to
the drug. Right, consistency is key. Consistency
is king. And we're not just eyeballing it, you
know? Right. We're taking precise measurements
using standardized procedures. Makes sense. And
what about blood work? Oh, blood work is crucial.
We do a bunch of lab tests, hematology, that's
all about your blood cells, making sure they're
healthy, the counts are good. Okay. Then there's
clinical chemistry, which tells us about how
your organs are functioning, liver, kidneys,
all the important stuff. Right, essential stuff.
Absolutely. Plus, we check electrolyte levels
and other markers that can tell us how the body
is reacting to the drug. So is there a standard
set of blood tests? Or does it depend on the
drug and the condition? Good question. It definitely
depends. It's all tailored to the specific drug
and the disease we're studying. Custom -made
lab panel, basically. Exactly. It's not one -size
-fits -all. And beyond the blood work, we also
do regular physical exams to get a sense of the
participants' overall health. Good old -fashioned
checkup. Can't beat it. And something that's
become increasingly important is what we call
patient -reported outcomes. Patient -reported
outcomes. That sounds interesting. What's that
about? So this is info that comes directly from
the patients themselves. Okay. We ask them about
their symptoms, how they're feeling, how they
think the treatment is affecting their daily
life, that sort of thing. So it's not just about
the numbers, it's about how they're actually
experiencing things. Exactly. It's a really valuable
way to understand the impact of the drug from
the patient's perspective. I can see that. What
kind of things do you ask them about? All sorts
of things. We might ask them to rate their pain
levels, tell us about their fatigue, or use questionnaires
to assess their quality of life, their ability
to do everyday activities. Right, how it's affecting
their life overall. Exactly. And then, of course,
we also have what we call the efficacy endpoints.
Efficacy. Meaning, is it actually working? Got
it. These are the specific measurements that
tell us if the drug is having the effect we want
it to have on the disease. OK. So if it's a cancer
drug, the efficacy endpoint might be tumor shrinkage.
Exactly. Or if it's for Alzheimer's, it might
be improvement on certain cognitive tests. It
really depends on the disease and how we measure
improvement. So it's all about picking the right
measurements, the right endpoints to see if the
drug is actually making a difference. It's all
about the end points. And the key is choosing
ones that are sensitive enough to detect subtle
changes, especially in early stage trials. Sometimes
those changes might be small, but they can still
be meaningful. That makes sense. So it sounds
like you're gathering a ton of info from all
these different sources. A ton. It's a whole
holistic approach, looking at the big picture,
not just one piece of the puzzle. We want to
see how the drug is affecting the whole person,
not just their disease. Right. And you said before,
that everything is tailored to the specific drug
and the condition? Always. There's no cookie
cutter approach here. Gotcha. So let's talk logistics
for a second. All this data you're collecting.
Yeah. How do you actually capture it and manage
it all during a phase two trial? It seems like
it would be a nightmare to keep track of everything.
It's a lot, that's for sure. In the old days,
it was all done on paper. Imagine these big,
thick forms called case report forms, or CRFs.
CRFs, okay. And every patient got one. Every
time they came in for a visit, the researchers
would fill out these forms, record all the data,
every little detail. So a whole stack of paperwork
for each person. Exactly. And then they had to
store all those forms, analyze them. It was a
huge headache. I bet. And prone to errors too,
I imagine. Oh yeah, handwriting mistakes, missing
data. It was a recipe for disaster. But thankfully
things have moved on since then. So what do you
use now? Now it's all electronic. We use these
systems called electronic data capture systems,
or EDC systems for short. EDCs. So it's like
a digital version of those paper forms. Exactly.
Now, instead of scribbling things down, the researchers
enter the data directly into a secure computer
system. Sounds much more efficient. It is. So
much faster, less room for errors, and way easier
to analyze the data later on. And I'm guessing
there are rules about using electronic systems
for medical data, right? Oh absolutely, there
are strict regulations especially in the US with
the FDA. Makes sense. So what kind of rules are
we talking about? Well, the big one is something
called 21 CFR Part 11. It's all about making
sure that electronic records are trustworthy,
that they're accurate, and that they can't be
tampered with. So it's about data integrity,
basically. Exactly. It's like having a digital
chain of custody for the data. So, for example,
if a doctor enters a patient's blood pressure
into the system, 21 CFR Part 11 makes sure that
there's a record of who entered it, when they
entered it, and if anyone made any changes to
it later on. So everything is tracked and documented.
Everything. And that's really important for the
FDA. They need to know that the data they're
getting is reliable and hasn't been manipulated
in any way. Makes sense. So these EDC systems
are basically a game changer for managing data
in clinical trials. They really are. They've
made things so much more efficient and accurate.
OK. So we've talked about safety monitoring.
But let's switch gears now and talk about the
other big goal of phase two, figuring out if
the drug is actually working. Right, we want
to see those early signs of efficacy, those hints
that the drug is having the desired effect. So
how do you actually track that? Well, it all
comes back to those efficacy endpoints we talked
about before, those specific measurements that
tell us if the drug is working. Right, like tumor
shrinkage or improved cognitive function. Exactly.
So throughout the trial, we're carefully monitoring
those endpoints in the group of people getting
the drug and comparing them to the control group.
The control group, right, the people who aren't
getting the drug. Exactly. They might get a placebo
or they might get a standard treatment that's
already available. And what we're looking for
for is a statistically significant difference
between the two groups. Meaning a difference
that's big enough that it's probably not just
due to chance. Exactly. And not only statistically
significant, but also clinically meaningful.
Meaning it actually makes a real difference in
people's lives. Exactly. So we're looking for
changes in those endpoints that suggest the drug
is having a real positive impact on the disease.
And in some phase two trials, we might do something
called an interim analysis. An interim analysis.
What's that? It's basically a sneak peek at the
data before the trial is finished. Oh, interesting.
So why would you want to look at the data before
the trial is over? There are a few reasons. First
of all, if the drug is showing a really clear
benefit early on, We might stop the trial early
for ethical reasons. Ethical reasons. Yeah, because
it wouldn't be fair to keep the people in the
control group from getting a drug that we already
know is working well. Ah, I see. So everyone
gets a chance to benefit. Exactly. And on the
flip side, if the data shows that the drug isn't
working or if there are serious safety concerns,
we might also stop the trial early to prevent
people from being exposed to unnecessary risks.
So it's a way to make sure that the trial is
still ethical and safe. even while it's ongoing.
Exactly. And those interim analyses can also
give us valuable information that helps us adjust
the trial design. Adjust the design? How so?
Well, for example, we might decide to change
the dose of the drug based on how people are
responding. Or maybe change who's eligible to
participate in the trial. Exactly. So it allows
for a more flexible approach, making sure we're
getting the best possible data from the trial.
Makes sense. It's like course correction mid
-flight. Exactly. And speaking of course correction,
what happens if something does go wrong during
the trial? Right, like a safety issue pops up
or becomes clear that the drug just isn't working.
Yeah, those are the moments when you really need
to have a plan. And thankfully, we do. We have
rapid response strategies in place to deal with
those kinds of situations. OK, so let's talk
about those. What are the key elements of a rapid
response strategy? Well, first of all, it's all
about being proactive. You can't just wait for
something bad to happen. You have to be actively
looking for any red flags. So constant monitoring,
basically. Constant vigilance. And then you need
to have a clear plan for what to do if something
does go wrong. Like a step -by -step guide. Exactly.
Who needs to be notified? What information needs
to be gathered? What decisions need to be made?
It all needs to be spelled out in advance. So
there's no confusion or delay when something
happens. Exactly. You got to be ready to act
fast. And one of the most important parts of
the rapid response system is the Data Safety
Monitoring Board, or DSMB. DSMB. These are like
the independent watchdogs of the trial. Watchdogs.
Yeah. They're a group of experts, usually doctors,
statisticians, ethicists, who aren't directly
involved in running the trial. So they're impartial.
Objective. Totally and their job is to keep a
close eye on the safety data as it comes in.
They meet regularly, review everything, and if
they see anything concerning, they have the power
to recommend changes to the trial. They could
recommend lowering the dose, changing the eligibility
criteria, even stopping the trial altogether
if the risks outweigh the benefits. Wow, so they
have a lot of authority. They do. They're there
to protect the participants, first and foremost.
And alongside the DSMB, there are also ethics
committees that oversee the trial. They make
sure everything is being done ethically and that
the participants' rights are being protected.
So multiple layers of oversight to ensure safety.
Multiple layers. You can never be too careful
when you're dealing with people's health. And
if something serious does happen, like a participant
has a severe reaction to the drug, there's a
clear procedure for reporting it to the authorities.
The authorities meaning? The FDA and the U .S.
or other regulatory agencies around the world.
Right. So they can investigate and take action
if necessary. Exactly. And sometimes, based on
what we learned during the trial, we might need
to make changes to the trial plan itself, the
protocol. So the protocol isn't set in stone.
It can be adapted. Absolutely. We might need
to adjust the dose, change the inclusion criteria,
add new safety monitoring procedures. It all
depends on what the data tells us. So it's a
dynamic process, constantly evolving. It is.
We're always learning and adjusting based on
what we're seeing. And those protocol amendments
are crucial for making sure the trial stays safe
and scientifically sound. Okay, this has been
really helpful, breaking down all the different
aspects of monitoring in Phase 2. Now, our research
for this deep dive covers a pretty broad range
of topics, right? But well -wide, yeah. And they
don't always give specific examples related to
Phase 2 monitoring. But do you think we can connect
some of these broader ideas, some of the concepts
we've explored, back to this crucial stage of
drug development? Oh, for sure. We can definitely
draw some parallels. Remember we talked about
how drugs are metabolized, broken down by the
body? Yeah, and those CYP enzymes, right? Like
CYP3A4. Exactly. So let's say in pre -clinical
studies we find out that our drug is mainly broken
down by a specific enzyme. Well, in phase two,
we're going to be really careful about monitoring
drug levels in patients' blood. Why is that so
important? Because people can have different
levels of those enzymes thanks to their genes
or other meds they're taking. And those variations
can make a big difference on how much drug is
actually active in their body. So someone might
need a higher dose or maybe they need a lower
dose to avoid side effects? Exactly. So understanding
those pharmacokinetic processes, you know, how
the drug is absorbed, distributed, metabolized,
eliminated, that's really key for interpreting
the phase two data, both the good stuff and the
bad stuff. Right. It helps you make sense of
why people are responding the way they are. Exactly.
And we also talked about those structural alerts
and medicinal chemistry. Remember? Legally. Remind
me. OK. So basically, There are certain chemical
features in a drug molecule that can make it
more likely to form toxic byproducts. Oh, right.
Those red flags in the drug's structure. Exactly.
Now, ideally, we'd identify those red flags early
on, even before phase two. But phase two is still
a time to be extra vigilant, especially if the
drug has one of those structural alludes. So
what kind of extra monitoring would you do in
that case? Well, we might do specific lab tests
to look for signs of organ damage that could
be caused by those toxic byproducts. products,
you're basically playing detective, looking for
any clues that something might be off. Interesting.
And we also discussed how medicinal chemists
try to tweak the drug's structure, maybe by changing
those heterocyclic groups to make it more effective.
Yeah, that's a big part of what they do. But
could those structural changes also affect safety?
Absolutely. It's all connected. They're not just
trying to make the drug more potent. They're
also trying to make it safer. So they're aiming
for that sweet spot. Maximum effectiveness, minimum
risk. Exactly. And those tweaks to the drug structure
can definitely influence what we need to watch
out for in phase two. Okay, so the design of
the drug itself is feeding into the safety monitoring
plan. And of course, we can't forget about the
FDA and the ICH, those regulatory bodies you
mentioned earlier. The regulatory landscape,
always a key player. Yeah, and their guidelines
seem to really shape how phase two trials are
run. Can you tell us a bit more about that? Sure.
So the FDA, before they even let you start testing
a drug in humans, they want to see a ton of data
from those preclinical studies, the pharmacology,
the toxicology. Right. They want to make sure
it's not going to kill anyone. Exactly. And that
sets the stage for really rigorous safety monitoring
once you do start testing in people. So those
preclinical studies are like the foundation for
everything that comes after. Absolutely. And
then you have all those ICH guidelines. good
clinical practice or GCP. That's like the Bible
for how to run clinical trials ethically and
scientifically. Okay, the rule book, basically.
Exactly. And there are specific guidelines for
safety pharmacology, too, that outline what kinds
of safety tests need to be done early on in drug
development. And those tests would inform what
you're specifically monitoring in phase two.
Exactly. They help you pinpoint what to watch
out for. And then there's ICH Q9, which is all
about managing risks. Risk management. Yeah,
it emphasizes being proactive, thinking ahead
about what could go wrong, and having plans in
place to prevent it or mitigate it. And that
applies to everything in drug development, including
phase two monitoring. So it's not just about
reacting to problems. It's about anticipating
them and trying to avoid them in the first place.
Exactly. And all these regulations, all these
guidelines, they're there for a reason. They're
there to protect the participants and make sure
that the data we're getting from these trials
is reliable and trustworthy. So it's a highly
regulated environment for good reason. It's all
about balancing that pursuit of new treatments
with the absolute priority of patient safety.
It's a delicate balance, but it's absolutely
essential. Okay, I think we've covered a lot
of ground here. For our listeners who might be
new to all this, let's try to summarize the key
takeaways about monitoring safety and efficacy
in phase two clinical trials. Okay, so the big
picture is this. Phase two monitoring is all
about walking that tightrope between carefully
evaluating the safety of the drug in people who
have the condition we're targeting and getting
those first clues about whether the drug actually
worked. Those early signals of efficacy. Exactly.
And that involves collecting a ton of data adverse
events, vital signs, lab results, patient reported
outcomes, all of it. And we use sophisticated
systems to manage all that data, make sure it's
accurate, and analyze it properly. And it's not
just about collecting data passively. Right?
There's this constant vigilance, this active
search for any signs of trouble. Always on the
lookout. And we have those independent watchdogs,
the DSMBs and ethics committees to keep an eye
on things and make recommendations if needed.
And if something does go wrong, we have those
rapid response plans ready to go. Inform the
authorities, adapt the trial protocol, whatever
it takes to protect the participant. Exactly.
And all of this happens within a very specific
regulatory framework, those rules set out by
the FDA and the ICH. So it's a carefully controlled
and constantly evolving process. Very much so.
And phase two is a crucial filter in drug development.
It helps us figure out which drugs have the potential
to be safe and effective and which ones we need
to abandon. Right. It helps us make those tough
decisions about which drugs to move forward with
and which ones to leave behind. It's a critical
stage. It really determines the fate of a drug.
And it raises a really interesting question,
you know, as we move into the future of medicine.
OK, what's the question? Well, we're seeing all
these new, really complex treatments being developed,
biologics, gene therapies, drugs designed by
AI. And it makes you wonder. How are we going
to adapt our monitoring system, our safety protocols,
to keep up with these advances? How do we make
sure we're still protecting patients while also
fostering innovation? That is a great question.
It's like the next frontier of drug development.
It is. It's a challenge, but it's also an exciting
time. Well, I think we've given our listeners
a lot to think about today. Thanks for walking
us through this complex and crucial world of
phase two clinical trials. My pleasure. Always
happy to dive deep. And for our listeners, thanks
for joining us on this deep dive. We'll be back
next time with another fascinating topic from
the world of science and medicine.